Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism

Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.

Guardado en:
Detalles Bibliográficos
Autores principales: Yunlong Yang, Yin Zhang, Hideki Iwamoto, Kayoko Hosaka, Takahiro Seki, Patrik Andersson, Sharon Lim, Carina Fischer, Masaki Nakamura, Mitsuhiko Abe, Renhai Cao, Peter Vilhelm Skov, Fang Chen, Xiaoyun Chen, Yongtian Lu, Guohui Nie, Yihai Cao
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2016
Materias:
Q
Acceso en línea:https://doaj.org/article/79582752f03043d7b3b6d8145bb72174
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:79582752f03043d7b3b6d8145bb72174
record_format dspace
spelling oai:doaj.org-article:79582752f03043d7b3b6d8145bb721742021-12-02T17:31:50ZDiscontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism10.1038/ncomms126802041-1723https://doaj.org/article/79582752f03043d7b3b6d8145bb721742016-09-01T00:00:00Zhttps://doi.org/10.1038/ncomms12680https://doaj.org/toc/2041-1723Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.Yunlong YangYin ZhangHideki IwamotoKayoko HosakaTakahiro SekiPatrik AnderssonSharon LimCarina FischerMasaki NakamuraMitsuhiko AbeRenhai CaoPeter Vilhelm SkovFang ChenXiaoyun ChenYongtian LuGuohui NieYihai CaoNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Yunlong Yang
Yin Zhang
Hideki Iwamoto
Kayoko Hosaka
Takahiro Seki
Patrik Andersson
Sharon Lim
Carina Fischer
Masaki Nakamura
Mitsuhiko Abe
Renhai Cao
Peter Vilhelm Skov
Fang Chen
Xiaoyun Chen
Yongtian Lu
Guohui Nie
Yihai Cao
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
description Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.
format article
author Yunlong Yang
Yin Zhang
Hideki Iwamoto
Kayoko Hosaka
Takahiro Seki
Patrik Andersson
Sharon Lim
Carina Fischer
Masaki Nakamura
Mitsuhiko Abe
Renhai Cao
Peter Vilhelm Skov
Fang Chen
Xiaoyun Chen
Yongtian Lu
Guohui Nie
Yihai Cao
author_facet Yunlong Yang
Yin Zhang
Hideki Iwamoto
Kayoko Hosaka
Takahiro Seki
Patrik Andersson
Sharon Lim
Carina Fischer
Masaki Nakamura
Mitsuhiko Abe
Renhai Cao
Peter Vilhelm Skov
Fang Chen
Xiaoyun Chen
Yongtian Lu
Guohui Nie
Yihai Cao
author_sort Yunlong Yang
title Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
title_short Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
title_full Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
title_fullStr Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
title_full_unstemmed Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
title_sort discontinuation of anti-vegf cancer therapy promotes metastasis through a liver revascularization mechanism
publisher Nature Portfolio
publishDate 2016
url https://doaj.org/article/79582752f03043d7b3b6d8145bb72174
work_keys_str_mv AT yunlongyang discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT yinzhang discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT hidekiiwamoto discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT kayokohosaka discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT takahiroseki discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT patrikandersson discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT sharonlim discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT carinafischer discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT masakinakamura discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT mitsuhikoabe discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT renhaicao discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT petervilhelmskov discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT fangchen discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT xiaoyunchen discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT yongtianlu discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT guohuinie discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
AT yihaicao discontinuationofantivegfcancertherapypromotesmetastasisthroughaliverrevascularizationmechanism
_version_ 1718380499512066048